c19early.org COVID-19 treatment researchCOVID-19 treatments

Supplementary Data — Ensovibep for COVID-19: real-time meta-analysis of 2 studies

@CovidAnalysis, November 2026, Version 9V9 (V1 2022)

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

Ensovibep COVID-19 outcomes

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Kingsley (DB RCT)89%0.11 · 0.01–2.27death0/3012/99EMPATHY Kingsley (DB RCT)78%0.22 · 0.06–0.76hosp./ER4/3016/99EMPATHY Kingsley (DB RCT)87%0.13 · 0.03–0.67hosp.2/3015/99EMPATHY Kingsley (DB RCT)87%0.13 · 0.03–0.67misc.2/3015/99EMPATHY Kingsley (DB RCT)30%0.70 · 0.44–1.11no recov.100 (n)99 (n)EMPATHY Kingsley (DB RCT)39%0.61 · 0.39–0.95no recov.100 (n)99 (n)EMPATHY Kingsley (DB RCT)39%0.61 · 0.39–0.95no recov.101 (n)99 (n)EMPATHY Kingsley (DB RCT)−1%1.01 · 0.82–1.24PASC146/24350/84EMPATHY Barkauskas (DB RCT)28%0.72 · 0.46–1.14death33/24743/238ACTIV-3/TICO Barkauskas (DB RCT)17%0.83 · 0.51–1.35death30/24735/238ACTIV-3/TICO Barkauskas (DB RCT)11%0.89 · 0.65–1.20death/hosp.80/24785/238ACTIV-3/TICO Barkauskas (DB RCT)6%0.94 · 0.78–1.14no recov.44/24748/238ACTIV-3/TICO Barkauskas (DB RCT)−8%1.08 · 0.77–1.49no recov.247 (n)238 (n)ACTIV-3/TICO Barkauskas (DB RCT)7%0.93 · 0.78–1.11no disch.28/24734/238ACTIV-3/TICO

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Ensovibep
reduces riskEnsovibep
increases risk →

Fig. S1. All outcomes.